FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986655894> ?p ?o ?g. }

• W1986655894 endingPage "3421" @default.
• W1986655894 startingPage "3411" @default.
• W1986655894 abstract "Article13 July 2006free access Unique anti-apoptotic activity of EAAC1 in injured motor neurons Sumiko Kiryu-Seo Sumiko Kiryu-Seo Department of Anatomy and Neurobiology, Osaka City University, Graduate School of Medicine, Abeno-ku, Osaka, Japan Search for more papers by this author Kazushige Gamo Kazushige Gamo Department of Anatomy and Neurobiology, Osaka City University, Graduate School of Medicine, Abeno-ku, Osaka, Japan Search for more papers by this author Taro Tachibana Taro Tachibana Department of Applied and Bioapplied Chemistry, Graduate School of Engineering, Osaka City University, Sumiyoshi-ku, Osaka, Japan Search for more papers by this author Kohichi Tanaka Kohichi Tanaka Laboratory of Molecular Neuroscience, School of Biomedical Science and Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan Search for more papers by this author Hiroshi Kiyama Corresponding Author Hiroshi Kiyama Department of Anatomy and Neurobiology, Osaka City University, Graduate School of Medicine, Abeno-ku, Osaka, Japan Search for more papers by this author Sumiko Kiryu-Seo Sumiko Kiryu-Seo Department of Anatomy and Neurobiology, Osaka City University, Graduate School of Medicine, Abeno-ku, Osaka, Japan Search for more papers by this author Kazushige Gamo Kazushige Gamo Department of Anatomy and Neurobiology, Osaka City University, Graduate School of Medicine, Abeno-ku, Osaka, Japan Search for more papers by this author Taro Tachibana Taro Tachibana Department of Applied and Bioapplied Chemistry, Graduate School of Engineering, Osaka City University, Sumiyoshi-ku, Osaka, Japan Search for more papers by this author Kohichi Tanaka Kohichi Tanaka Laboratory of Molecular Neuroscience, School of Biomedical Science and Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan Search for more papers by this author Hiroshi Kiyama Corresponding Author Hiroshi Kiyama Department of Anatomy and Neurobiology, Osaka City University, Graduate School of Medicine, Abeno-ku, Osaka, Japan Search for more papers by this author Author Information Sumiko Kiryu-Seo1, Kazushige Gamo1, Taro Tachibana2, Kohichi Tanaka3 and Hiroshi Kiyama 1 1Department of Anatomy and Neurobiology, Osaka City University, Graduate School of Medicine, Abeno-ku, Osaka, Japan 2Department of Applied and Bioapplied Chemistry, Graduate School of Engineering, Osaka City University, Sumiyoshi-ku, Osaka, Japan 3Laboratory of Molecular Neuroscience, School of Biomedical Science and Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan *Corresponding author. Department of Anatomy and Neurobiology, Osaka City University, Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan. Tel.: +81 6 6645 3701; Fax: +81 6 6645 3702; E-mail: [email protected] The EMBO Journal (2006)25:3411-3421https://doi.org/10.1038/sj.emboj.7601225 PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Injured motor neurons of the adult rat can survive, whereas similar axotomy causes gradual motor neuron death in the adult mouse. We report that the decreased expression of the neuronal glutamate transporter excitatory amino-acid carrier 1 (EAAC1) following nerve injury is associated with motor neuron death in the mouse. Glutamate transporters play a crucial role in prevention of neuronal death by suppressing glutamate toxicity. However, the possible functional role of EAAC1 in preventing neuron death has not been resolved as compared with glial glutamate transporters such as GLT-1. Here, we have revealed a unique ‘rescue’ function of EAAC1, which is independent of removal of extracellular glutamate. During apoptotic stimuli, a mitochondrial protein, holocytochrome c synthetase (HCCS), translocates to outside the mitochondria, binds to and suppresses the X-linked inhibitor of apoptosis protein (XIAP), leading to activation of caspase-3. The N-terminus of EAAC1 can bind to HCCS, which interferes with the HCCS–XIAP association, and thereby maintain XIAP activity. This unique anti-apoptotic mechanism of EAAC1 functions in rescuing PC12 cells and motor neurons from NGF deprivation and nerve injury, respectively. Introduction Peripheral nerve-injured motor neurons in the adult rats can survive and subsequently regenerate; however, those in adult mice undergo progressive neuronal death over a period of several weeks (Kiryu-Seo et al, 2005). The motor neuronal death seen in the adult mice progresses at a much slower rate than that seen in the neonatal animals (Snider et al, 1992), because most of the major anti-apoptotic mechanisms including neurite elongation appear to function in the injured neurons of adult mice as well as in those of adult rats (Kiryu-Seo et al, 2005). The slower motor neuron death seen in adult mice could therefore be an interesting and appropriate model for investigating neurodegenerative diseases such as amyotrophic lateral sclerosis rather than the relatively acute motor neuron death seen in neonates. It seemed likely that an important but slowly acting part of the neuronal survival machinery is missing in the motor neurons of adult mice, but is present in those of adult rats, leading to the gradual death of mouse motor neurons. We therefore looked for the missing part of the survival machinery by screening for nerve injury-associated genes in rats and mice, and focused on the neuronal glutamate transporter excitatory amino-acid carrier 1 (EAAC1) as a candidate gene. The expression of EAAC1 was upregulated in rat motor neurons after axotomy (Kiryu et al, 1995), but downregulated in mouse, suggesting that EAAC1 might have an important role in the prevention of motor neuronal death in the rat. Of the molecules implicated in glutamate clearance, five members of high-affinity Na+-dependent excitatory amino-acid transporters (EAATs) have so far been discovered: GLAST/EAAT1, GLT-1/EAAT2, EAAC1/EAAT3, EAAT4 and EAAT5 (Danbolt, 2001). Of the glutamate transporters that have been described, the glial type glutamate transporters such as GLAST/EAAT1 and GLT-1/EAAT2 are the major glutamate transporters in the central nervous system (CNS) and are predominantly localized on astrocyte membranes. They are assumed to play a major role in preventing glutamate-induced neuronal death, as well as terminating glutamatergic synaptic transmission (Choi, 1988; Rothstein et al, 1996). In particular, the functional relevance of EAAT2 was clearly demonstrated in a study using GLT1/EAAT2 knockout mice, which developed a phenotype characterized by severe epilepsy (Tanaka et al, 1997). By contrast, EAAC1/EAAT3, which is also widely expressed in CNS and predominantly localized in neuron (Kanai and Hediger, 1992), is unlikely to be a major player in suppression of glutamate toxicity. One reason is that EAAC1-deficient mice develop normally and without apparent neurodegeneration and epilepsy (Peghini et al, 1997). However, a recent study using EAAC1-deficient mice showed that EAAC1 can function as a cysteine transporter and maintain neuronal glutathione homeostasis (Aoyama et al, 2006). It is possible that EAAC1 may have alternative activities distinct from glutamate removal. After axotomy, motor neuron death is triggered by Fas and proceeds via the established mitochondrial death pathway (Martin and Liu, 2002; Ugolini et al, 2003; Martin et al, 2005). The motor neuron death seen in the mice also progresses gradually via the mitochondrial death pathway in a tumor suppressor protein p53-dependent manner (Kiryu-Seo et al, 2005). The mitochondria-dependent apoptotic machinery has been very well documented (Pettmann and Henderson, 1998; Ferri and Kroemer, 2001; Saelens et al, 2004). In general, the release of cytochrome c from mitochondria into the cytosol is pivotal in the activation of caspases and the ensuing cell death. Concurrent with cytochrome c release, other mitochondrial proteins such as Smac/DIABLO and Omi/HtrA2 are also released from mitochondria into the cytosol. They interact with inhibitor of apoptosis proteins (IAPs) and eliminate their inhibitory effects on caspase activity. However, their IAP suppression activity may be a secondary function occurring only during apoptotic stimuli, as these proteins are essential for maintaining mitochondrial function under normal condition (Jones et al, 2003; Martins et al, 2004). From database searches and knockout studies, there seem to be still many mitochondrial proteins with the potential to act as IAP binding proteins (Vaux and Silke, 2003; Martins et al, 2004). In this study, we report that EAAC1 has a unique action in preventing mitochondria-mediated neuronal death. This ‘rescue’ activity does not depend on glutamate removal, but requires an interaction with a mitochondrial protein, holocytochrome c synthetase (HCCS), which is released from the mitochondria. HCCS is normally localized in the mitochondrial intermembrane space and is essential for holo-cytochrome c synthesis (Schaefer et al, 1996). However, it is now evident that cytosolic HCCS may have a secondary role as an X-linked IAP (XIAP) binding protein under apoptotic stimuli. Here, we consider how EAAC1 may contribute to the survival of injured motor neurons. Results EAAC1 shows different expression patterns in rats and mice following axotomy Following hypoglossal nerve axotomy, injured motor neurons in rats survive and regenerate, whereas those in mice die over a period of several weeks. We found that the signal for EAAC1 mRNA was increased in rat injured motor neurons, but was decreased rapidly in the first days after axotomy in the mouse (Figure 1A and B). Our previous studies using in situ hybridization have demonstrated that most nerve injury-associated genes were regulated similarly in both the rat and the mouse at 7 days after axotomy (Kiryu-Seo et al, 2005). Consistent with this, expression of the other glutamate transporter family members such as GLT-1, GLAST and neutral amino-acid transporters, system ASC transporters (ASCT1 and ASCT2), also responded similarly in rats and mice following hypoglossal axotomy (Figure 2A). RT–PCR analysis using control and injured hypoglossal nuclei confirmed that the expression of all these transporters except for EAAC1 was regulated similarly in both rats and mice (Figure 2B). The upregulation of EAAC1 expression in rats was also observed after alternative peripheral nerve injuries, including facial and sciatic nerve axotomy (Supplementary Figure 1). As EAAC1 expression was unchanged after CNS lesion of rats (Ginsberg et al, 1995, 1996; Lievens et al, 2001), it suggests that this increased EAAC1 expression is critical for the survival of motor neurons in the rat. Figure 1.The regulation of EAAC1 mRNA expression is strikingly different in rats and mice following hypoglossal nerve injury. (A) Top panel: In situ hybridization showed that expression of EAAC1 mRNA was upregulated in the injured hypoglossal nucleus of rats, but downregulated in those of mice 7 days following axotomy. Bottom panel: Motor neurons stained with thionine at 7 days after nerve injury. The number of motor neurons did not change at this time point in rats and mice. cc, central canal; XII, hypoglossal nucleus. Scale bars, 100 μm for rat and 50 μm for mouse. (B) Change in EAAC1 mRNA expression after nerve injury in rats (closed circles) and mice (open circles). Each point shows the mean±s.d. of the relative signal intensity. The asterisks indicate statistically significant differences compared with the results found in rats (P<0.01; Student's t-test, n=4). Download figure Download PowerPoint Figure 2.The expression of mRNA for glutamate transporter family members after hypoglossal axotomy. (A) Expression of mRNA for glutamate transporter family members was examined by in situ hybridization 7 days after axotomy. EAAC1 mRNA was upregulated (closed arrow) in injured hypoglossal neurons of rat, but downregulated (open arrow) in those of mice. Scale bar, 1.3 mm for rat and 0.8 mm for mouse. (B) RT–PCR using total RNA from control (cont) and injured (inj) hypoglossal nuclei of rats and mice 7 days after axotomy. Download figure Download PowerPoint The expression of EAAC1 is correlated with the survival of injured motor neurons in mice To evaluate the relevance of EAAC1 expression to the survival of injured motor neuron, we used EAAC1 transgenic mice (on a C57BL/6 background) and EAAC1-deficient mice (on an ICR background). In EAAC1 transgenic mice, the damage-induced neuronal endopeptidase (DINE) promoter, which we have previously identified as a neuron-specific and injury-associated gene (Kiryu-Seo et al, 2000), was employed. This transgenic mouse was designed to express EAAC1 and GFP simultaneously by inserting an internal ribosome entry site under the control of the DINE promoter. Analysis of mRNA expression in the EAAC1 transgenic mice after axotomy showed that EAAC1 expression was maintained as might be expected because expression of exogenous EAAC1 was increased after nerve injury (Figure 3A and B and Supplementary Figure 2). We then counted the number of surviving motor neurons in wild-type and EAAC1 transgenic mice. As we have described previously, 35 days after nerve injury is a good time point to evaluate neuronal survival and compare the response of the different animals (Kiryu-Seo et al, 2005). At 35 days after axotomy, the wild-type mice had lost approximately 50% of neurons in the injured hypoglossal nuclei. In contrast, the EAAC1 transgenic mice exhibited significantly less neuronal death (Figure 3C and D). This suggests strongly that EAAC1 overexpression in the mouse may mimic the phenotypic response of injured rat motor neurons. In EAAC1-deficient mice (ICR background), there was an accelerated loss of injured neurons as compared with wild-type mice (Figure 3E and F). RT–PCR analysis using hypoglossal nuclei of both EAAC1 transgenic and knockout mice showed that expression of the members of the glutamate transporter family was regulated similarly (Figure 3G). As shown in Figure 3C–F, the survival rate of injured neuron was different between the two mouse strains, C57BL/6 and ICR. Thus, we also examined the effect of genetic background on the motor neuron death after axotomy (Supplementary Figure 3A). At 35 days after axotomy, the survival of neurons in wild-type ICR mice was about 80%, whereas that in wild-type C57BL/6 mice was around 50%. Both strains showed downregulation of EAAC1 mRNA after nerve injury; however, the level of downregulation of EAAC1 mRNA in the two strains correlated well with the survival of axotomized neurons (Supplementary Figure 3B and C). All these data further suggest an important role for EAAC1 in the survival of nerve-injured adult mouse motor neurons. Figure 3.EAAC1 expression influences the survival of injured motor neurons. (A) Sections of hypoglossal motor neurons from wild-type mice (WT) and EAAC1-overexpressing mice (Tg EAAC1) 35 days after axotomy (C57BL/6 background) were subjected to in situ hybridization to examine the expression of EAAC1 mRNA. (B) RT–PCR using hypoglossal nuclei of WT and Tg EAAC1 7 days after axotomy. (C) Thionine staining of hypoglossal nuclei 35 days after axotomy. (D) Percentage of surviving neurons 35 days after axotomy. Results represent the percent ratio of surviving motor neurons on the injured side compared with the contralateral side. Data are mean±s.d. (P<0.01; Student's t-test, n=7). (E) Thionine staining of hypoglossal motor neurons 35 days after hypoglossal nerve injury in WT mice and EAAC1-deficient mice (EAAC1 KO) (ICR background). (F) Percentage of surviving motor neurons in WT and EAAC1 KO 35 days after axotomy. Data are mean±s.d. (P<0.01; Student's t-test, n=11). (G) RT–PCR analysis using hypoglossal nuclei from Tg EAAC1 and EAAC1 KO 7 days after nerve injury. cc, central canal; XII, hypoglossal nucleus; control, contralateral side; injured, injured side; cont, contralateral side; inj, injured side. Scale bar, 50 μm (A,C, E). The asterisks indicate statistically significant differences compared with the results of WT mice (D, F). Download figure Download PowerPoint EAAC1 prevents neuronal death in differentiated PC12 cells To examine how EAAC1 may prevent neuronal death, we carried out in vitro studies. We first demonstrated that differentiated PC12 neuronal cells overexpressing EAAC1 took up 14C-labeled glutamate more effectively than control cells (Figure 4A). Expression of EAAC1 in these cells did not alter their level of expression of other glutamate transporters (Supplementary Figure 4A). Although previous reports have indicated that EAAC1 may take up cysteine as well as glutamate (Zerangue and Kavanaugh, 1996; Chen and Swanson, 2003), both EAAC1-overexpressing and control PC12 cells showed similar uptake of cysteine (Supplementary Figure 4B). This may be because PC12 cells express enough endogenous ASCTs (Supplementary Figure 4A). Figure 4.EAAC1 rescues differentiated PC12 cells from cell death after NGF deprivation. (A) Glutamate uptake activity and an immunoblot in control or EAAC1 adenovirus-infected differentiated PC12 cells. Uptake activity is expressed as a percentage of that in control cells (mean±s.d., P<0.01; Student's t-test). (B) Cell viability of differentiated PC12 cells infected with control (dotted bar) or EAAC1 (closed bar) adenoviruses was measured at 0, 24 and 48 h after NGF withdrawal (mean±s.d., P<0.01; Student's t-test). (C) Caspase-3-like activity of differentiated PC12 with control (dotted bar) or EAAC1 (closed bar) adenoviruses was measured at 0 and 9 h after NGF withdrawal. Data are expressed as fold increase compared with nontreated cells (mean±s.d., P<0.01; Student's t-test). (D) Immunoblots of cytoplasmic cleaved caspase-3 and cytochrome c following NGF withdrawal. (E) Immunoblots of suppression of endogenous EAAC1 expression by antisense oligonucleotide and the associated increase in caspase-3 activity. S, sense oligonucleotide; R, random oligonucleotide; AS, antisense oligonucleotide. (F) Glutamate uptake activity in COS-7 cells transfected with indicated plasmids tagged with HA. Data are mean±s.d. (G) Cell surface biotinylation assay using COS-7 cells transfected with the plasmids tagged with HA. (H) Immunoblot of cleaved caspase-3 in differentiated PC12 cells transfected with indicated plasmids tagged with HA. At 48 h after transfection, NGF was withdrawn for 6 h. (I) Immunoblot of cleaved caspase-3. Differentiated PC12 cells were deprived of NGF for 6 h after application of 17-amino-acid peptide (EAAC1 (1–17) peptide). Download figure Download PowerPoint As the motor neuron death seen in adult mouse is mediated by the mitochondrial death pathway in a p53-dependent manner, it is likely that EAAC1 may act to suppress the mitochondrial death pathway either directly or indirectly. To investigate the possible involvement of EAAC1 in prevention of the mitochondria-mediated death pathway, we examined the effect of EAAC1 overexpression in differentiated PC12 neuronal cells on neuronal survival after NGF withdrawal, which is known to be accompanied by activation of the p53 pathway (Supplementary Figure 4C) (Vaghefi et al, 2004). After NGF withdrawal, EAAC1-expressing PC12 cells exhibited a significant increase in viability as compared to control cells and significantly less activation of caspase-3 (Figure 4B–D). This EAAC1 rescue activity was also observed after p53 adenovirus infection (Supplemental Figure 4D and E). Conversely, knockdown of endogenous EAAC1 expression in PC12 cells by treatment with EAAC1 antisense oligonucleotides significantly induced caspase-3 activity, even in NGF-containing culture medium (Figure 4E). In general, glutamate transporters have been considered to promote neuron survival activity by reducing extracellular/excitotoxic glutamate levels. However, our findings suggest that EAAC1 has an additional anti-apoptotic activity distinct from its ability to remove extracellular glutamate. N-terminus of EAAC1 is required for survival To examine whether EAAC1 indeed has another physiological function distinct from glutamate clearance during apoptotic stimuli, we carried out preliminary experiments using some deletion mutants and demonstrated an important role for the N-terminal domain of EAAC1. The function of the N-terminal domain, whose amino-acid sequence diverges most from those of other glutamate transporter family members, is obscure. N-terminal-deleted EAAC1 (ΔN-EAAC1)-expressing cells showed comparable glutamate uptake activity, although the activity was a little lower than that of wild-type EAAC1- and GLT-1-expressing cells, probably because of protein instability (Figure 4F). This result was consistent with protein levels expressed on the cell surface (Figure 4G). In spite of the similar glutamate uptake activity, a striking difference was that the wild-type EAAC1 effectively inhibited caspase-3 activation after NGF deprivation in differentiated PC12 cells, whereas ΔN-EAAC1-expressing cells did not suppress caspase-3 activity (Figure 4H). GLT-1-expressing cells also failed to suppress caspase-3 activity, although they effectively took up glutamate (Figure 4F and G). When we introduced a 17-amino-acid sequence from the N-terminal domain of EAAC1 (peptide MGKPTSSGCDWRRFLRN) into PC12 cells, this peptide effectively inhibited caspase-3 activity as shown in Figure 4I. These results strongly suggest that the N-terminal domain of EAAC1 may play a crucial role in this ‘rescue’ activity, and this ‘rescue’ activity is distinct from its activity associated with glutamate clearance. It seemed highly likely that a molecule that might suppress caspase-3 activity either directly or indirectly may be associated with the N-terminus of EAAC1. EAAC1 binds to a proapoptotic mitochondrial protein, HCCS To identify possible proteins binding to the N-terminal region of EAAC1, we carried out yeast two-hybrid screening. Of the positive clones, a strongly interacting clone was found to encode HCCS (also known as CCHL or heme lyase) (Schaefer et al, 1996). HCCS is a mitochondrial protein, which converts apo-cytochrome c to holo-cytochrome c by attaching heme in the intermembrane space of mitochondria. First, we showed that endogenous HCCS co-immunoprecipitated with endogenous EAAC1 in differentiated PC12 cells, suggesting that the interaction is physiologically significant (Figure 5A). The next question was how the interaction between EAAC1 and HCCS occurred in spite of their different subcellular localizations. We speculated that HCCS might be released from mitochondria and promote cell death, because many mitochondrial proteins including Smac/DIABLO and Omi/HtrA2 are released into the cytoplasm under apoptotic stimuli and initiate the apoptotic cascade. Therefore, we examined the translocation of endogenous HCCS from the mitochondria into the cytoplasm after NGF deprivation of differentiated PC12 cells, which is the typical neuronal apoptotic paradigm (Figure 5B and C). Immunostaining showed that HCCS was clearly colocalized with cytochrome c in mitochondria in normal PC12 cells. However, after NGF withdrawal, HCCS staining had spread diffusely into the cytoplasm (Figure 5B). In addition, Western blotting using mitochondrial and cytosolic fractions showed that the amount of endogenous HCCS and cytochrome c immunoreactivity in the fractions containing mitochondria were decreased by 3 and 6 h after NGF deprivation (Figure 5C). In contrast, an increased level of HCCS was detected in the cytosolic fraction after NGF deprivation, suggesting that endogenous HCCS may be released from the mitochondria into the cytoplasm as in the classic model of neuronal apoptosis. Furthermore, overexpression of HCCS made the cells more susceptible to death signals such as NGF withdrawal (Figure 5D) and induced caspase-3 activation (Figure 5E). The caspase-3 activity was inhibited by additional expression of EAAC1. EAAC1 expression did not alter the level of HCCS protein (Supplementary Figure 6A). Figure 5.HCCS is released from mitochondria and binds to EAAC1. (A) Endogenous interaction between EAAC1 and HCCS in differentiated PC12 cells. Whole-cell lysates (WCL) from differentiated PC12 cells were lysed, subjected to immunoprecipitation (IP) with control IgG and anti-HCCS antibody and blotted (WB) with anti-EAAC1 and anti-HCCS antibodies. (B) Differentiated PC12 cells immunostained with anti-HCCS (red) and anti-cytochrome c (green) antibodies at 0 (NGF+) and 20 h after NGF withdrawal (NGF−). (C) Subcellular localization of endogenous HCCS in differentiated PC12 cells. After NGF deprivation, reduced levels of HCCS and cytochrome c were observed in the heavy membrane/mitochondrial fraction. Elevated levels of these proteins were observed in the cytosolic fraction. (D) Cell viability of differentiated PC12 cells transfected with control (dotted bar) or HCCS (closed bar) plasmids was measured at 0 and 36 h after NGF withdrawal (mean±s.d., asterisk denotes P<0.01; Student's t-test). (E) HCCS-mediated cleaved caspase-3 reaction in differentiated PC12 cells was reversed by cotransfection with EAAC1. The indicated expression vectors were overexpressed in differentiated PC12 cells for 48 h and thereafter collected at 0 (NGF+) and 6 h (NGF−) after NGF withdrawal. Download figure Download PowerPoint Precise interaction between EAAC1 and HCCS To verify more precisely the interaction between HCCS and EAAC1, we performed immunoprecipitation analysis using COS-7 cells. Initially, COS-7 cells were transiently transfected with cDNA encoding the C-terminal HA-tagged EAAC1 and GLT-1, together with FLAG-tagged HCCS (Figure 6A). HCCS immunoprecipitated wild-type EAAC1, but did not precipitate GLT-1. When COS-7 cells were transfected with C- and N-terminal HA-tagged EAAC1 together with FLAG-tagged HCCS, HCCS immunoprecipitated both forms of EAAC1 (Supplementary Figure 5). It seems that HCCS can interact with the full-length EAAC1, but not the N-terminus cleaved form of EAAC1. Next, we performed GST pull-down assays with in vitro-translated EAAC1 protein (Figure 6B). Bacterially produced GST-HCCS associated with wild-type EAAC1 protein, but failed to bind to ΔN-EAAC1. Furthermore, the N-terminal EAAC1 peptide competed with EAAC1 protein for binding to GST-HCCS in a dose-dependent manner (Figure 6C). To characterize the association between EAAC1 and HCCS further, we fragmented HCCS, attached FLAG tag and assayed the interaction using immunoprecipitation (Figure 6D). Wild-type EAAC1 strongly interacted with full-length HCCS encoding 272 amino acids and HCCS (148–272) lacking the heme-binding motif. In contrast, EAAC1 exhibited no detectable interaction with HCCS (1–152) lacking a mitochondria-targeting signal. These data showed that the EAAC1 N-terminus can bind to the C-terminal portion of HCCS. Figure 6.Precise interaction between EAAC1 and HCCS. (A) COS-7 cells were transfected with cDNA encoding HA-tagged EAAC1 (EAAC1-HA) or HA-tagged GLT-1 (GLT-1-HA) together with FLAG-tagged HCCS (FLAG-HCCS). At 36 h after transfection, cells were solubilized in RIPA buffer. Whole-cell lysates (WCL) from COS-7 cells were immunoprecipitated (IP) using anti-FLAG antibody, followed by Western blotting (WB) with anti-HA antibody. (B) GST pull-down assay with in vitro-translated wild-type and ΔN-EAAC1 protein. Top panel: Autoradiographic analysis showing the interaction between 35S-labeled EAAC1 and bacterially produced GST-tagged HCCS. Bottom panel: Coomassie blue-stained polyacrylamide gel (CBB) of GST fusion protein. (C) EAAC1 peptide competes with in vitro-translated EAAC1 protein for binding to GST-HCCS in a dose-dependent manner. Bound proteins were visualized by immunoblotting with anti-EAAC1 antibody. Bottom panel: Coomassie blue-stained polyacrylamide gel (CBB) of GST fusion protein. (D) COS-7 cells were transfected with EAAC1-HA and the indicated plasmids including deletion mutants of HCCS with attached FLAG tag. The EAAC1–HCCS interaction was examined by immunoprecipitation. Download figure Download PowerPoint HCCS is a member of a new family of IAP binding proteins We speculated that HCCS may have a role as IAP binding partner as has been established for Smac/DIABLO and Omi/HtrA2 and we looked at this possibility in more detail. Initially, we demonstrated that endogenous HCCS co-immunoprecipitated with endogenous XIAP in differentiated PC12 cells, suggesting that the interaction is indeed physiologically significant (Figure 7A). We then showed that GST-HCCS successfully interacted with the full-length 35S-labeled XIAP (Figure 7B). Next, expression plasmids for various N-terminal FLAG- or Myc-tagged IAPs, including XIAP, c-IAP1, c-IAP2 and survivin, were transiently transfected in COS-7 cells with a plasmid encoding the N-terminal HA-tagged HCCS. The HCCS was co-immunoprecipitated with XIAP, c-IAP1 and c-IAP2, but did not bind to survivin (Figure 7C). These results indicate that HCCS preferentially binds to some IAP members, such as XIAP, c-IAP1 and c-IAP2, with potent caspase-inhibitory activity. Figure 7.HCCS is a new member of IAP antagonists. (A) Endogenous interaction between HCCS and XIAP in differentiated PC12 cells. Whole-cell lysates (WCL) from differentiated PC12 cells were lysed, subjected to immunoprecipitation (IP) with control IgG and anti-HCCS antibody and blotted (WB) with anti-XIAP and anti-HCCS antibodies. (B) Top panel: Autoradiography showing the interaction between 35S-labeled XIAP and GST-tagge" @default.
• W1986655894 created "2016-06-24" @default.
• W1986655894 creator A5015382372 @default.
• W1986655894 creator A5018186082 @default.
• W1986655894 creator A5068238908 @default.
• W1986655894 creator A5075627852 @default.
• W1986655894 creator A5078580328 @default.
• W1986655894 date "2006-07-13" @default.
• W1986655894 modified "2023-10-09" @default.
• W1986655894 title "Unique anti-apoptotic activity of EAAC1 in injured motor neurons" @default.
• W1986655894 cites W1522763255 @default.
• W1986655894 cites W1562942145 @default.
• W1986655894 cites W1580427974 @default.
• W1986655894 cites W1607777232 @default.
• W1986655894 cites W1629134182 @default.
• W1986655894 cites W1664703379 @default.
• W1986655894 cites W1702242026 @default.
• W1986655894 cites W1965902234 @default.
• W1986655894 cites W1966798559 @default.
• W1986655894 cites W1969400861 @default.
• W1986655894 cites W1971001046 @default.
• W1986655894 cites W1979363543 @default.
• W1986655894 cites W1989862231 @default.
• W1986655894 cites W1997727568 @default.
• W1986655894 cites W2001803013 @default.
• W1986655894 cites W2002439304 @default.
• W1986655894 cites W2011200616 @default.
• W1986655894 cites W2013130478 @default.
• W1986655894 cites W2016084983 @default.
• W1986655894 cites W2016575029 @default.
• W1986655894 cites W2017998710 @default.
• W1986655894 cites W2026036357 @default.
• W1986655894 cites W2028002685 @default.
• W1986655894 cites W2031949901 @default.
• W1986655894 cites W2035360955 @default.
• W1986655894 cites W2039793049 @default.
• W1986655894 cites W2040286934 @default.
• W1986655894 cites W2042409437 @default.
• W1986655894 cites W2042451369 @default.
• W1986655894 cites W2045114648 @default.
• W1986655894 cites W2058763669 @default.
• W1986655894 cites W2065389632 @default.
• W1986655894 cites W2069473876 @default.
• W1986655894 cites W2072728982 @default.
• W1986655894 cites W2073953555 @default.
• W1986655894 cites W2090856415 @default.
• W1986655894 cites W2104773672 @default.
• W1986655894 cites W2110483280 @default.
• W1986655894 cites W2115687796 @default.
• W1986655894 cites W2121167030 @default.
• W1986655894 cites W2128744963 @default.
• W1986655894 cites W2131315270 @default.
• W1986655894 cites W2140166756 @default.
• W1986655894 cites W2140869185 @default.
• W1986655894 cites W2156945415 @default.
• W1986655894 cites W2160644313 @default.
• W1986655894 cites W2162653594 @default.
• W1986655894 cites W2162978926 @default.
• W1986655894 cites W2168008533 @default.
• W1986655894 cites W4210979710 @default.
• W1986655894 doi "https://doi.org/10.1038/sj.emboj.7601225" @default.
• W1986655894 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1523171" @default.
• W1986655894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16858406" @default.
• W1986655894 hasPublicationYear "2006" @default.
• W1986655894 type Work @default.
• W1986655894 sameAs 1986655894 @default.
• W1986655894 citedByCount "47" @default.
• W1986655894 countsByYear W19866558942012 @default.
• W1986655894 countsByYear W19866558942013 @default.
• W1986655894 countsByYear W19866558942014 @default.
• W1986655894 countsByYear W19866558942015 @default.
• W1986655894 countsByYear W19866558942016 @default.
• W1986655894 countsByYear W19866558942017 @default.
• W1986655894 countsByYear W19866558942018 @default.
• W1986655894 countsByYear W19866558942019 @default.
• W1986655894 countsByYear W19866558942021 @default.
• W1986655894 countsByYear W19866558942022 @default.
• W1986655894 countsByYear W19866558942023 @default.
• W1986655894 crossrefType "journal-article" @default.
• W1986655894 hasAuthorship W1986655894A5015382372 @default.
• W1986655894 hasAuthorship W1986655894A5018186082 @default.
• W1986655894 hasAuthorship W1986655894A5068238908 @default.
• W1986655894 hasAuthorship W1986655894A5075627852 @default.
• W1986655894 hasAuthorship W1986655894A5078580328 @default.
• W1986655894 hasBestOaLocation W19866558941 @default.
• W1986655894 hasConcept C169760540 @default.
• W1986655894 hasConcept C190283241 @default.
• W1986655894 hasConcept C54355233 @default.
• W1986655894 hasConcept C86803240 @default.
• W1986655894 hasConcept C95444343 @default.
• W1986655894 hasConceptScore W1986655894C169760540 @default.
• W1986655894 hasConceptScore W1986655894C190283241 @default.
• W1986655894 hasConceptScore W1986655894C54355233 @default.
• W1986655894 hasConceptScore W1986655894C86803240 @default.
• W1986655894 hasConceptScore W1986655894C95444343 @default.
• W1986655894 hasIssue "14" @default.
• W1986655894 hasLocation W19866558941 @default.
• W1986655894 hasLocation W19866558942 @default.

• next